Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing round, raising in excess of RMB100 million (USD14.04 million). The funding round was led by China Venture Capital, with participation from Betta Pharmaceuticals Co., Ltd (SHE: 300558) contributing RMB 20 million, Lenovo Capital and Incubator Group, and Lotus Lake Capital, among others. Ding Leming, the chairman and CEO of Betta Pharma, directly holds a 46.80% capital contribution in Reprogenix and is an executive director and the actual controller of the firm. Concurrently with the funding, Reprogenix and Betta Pharma have entered into a strategic partnership aimed at advancing the research into the induced differentiation of human pluripotent stem cells into pancreatic islet cells.
Reprogenix’s RGB-5088: A Pioneering Product for Type 1 Diabetes Treatment
Reprogenix prides itself on developing RGB-5088, the first indigenous pancreatic islet cells injection product in China. This product is also the first multipotent stem cell product to be filed for study in China for the treatment of type 1 diabetes, marking a significant milestone in the field of regenerative medicine.- Flcube.com
